RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Weekly Report CardThe fact that they never succeeded with institutional investors to me emphasize the need to initiate a retail strategy, there aren't any burned bridges there just a fresh start. Whatever data they have whether it's human, animal or freaking alien data go out there and market it.
How is that HEPA which just completed their phase 1 NASH is valued $144 M that would be about 44% of THTX's current valuation,no revenues, no oncology program? To put it in perspective a phase 1 trial has statistically 16% chance of ending up with an approved drug versus 64% for a phase 3 trial.
Their institutional ownership is about the same as THTX yet their average daily trading volume is millions! They have almost twenty times more followers on Stocktwits than THTX so they successfully engaged the retail segment thus fair valuation and decent volume. An effective retail marketing in my opinion should be a priority during the rebranding process.